Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.
Acute Myeloid Leukemia
DRUG: Ribavirin|DRUG: Vismodegib|DRUG: Decitabine
Efficacy will be measured by overall response rate (ORR)., Measured up to 2 years after the last subject has enrolled in the study.
Time to response, Measured up to 2 years after the last subject has enrolled in the study.|Duration of response, Measured up to 2 years after the last subject has enrolled in the study.|One year survival, Measured up to 2 years after the last subject has enrolled in the study.|Overall survival, Measured up to 3 years after the last subject has enrolled in the study.|Hematologic improvement defined by the number of individual, positively affected cell lines (erythroid, neutrophil and platelet cells) per patient., Measured up to 2 years after the last subject has enrolled in the study.|Number of participants with Adverse Events as a Measure of Safety and Tolerability, Measured up to 2 years after the last subject has enrolled in the study.|Changes in eIF4E expression, localization, and signalling pathways (measured by immuno-histochemical analysis, PCR or western blot) and correlating with each patient's overall response., Measured up to 2 years after the last subject has enrolled in the study.
This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.